| DC42273 |
PSI-7976 |
PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity. |
|
| DC42274 |
Sofosbuvir impurity A |
Sofosbuvir impurity A, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity. |
|
| DC42275 |
Grazoprevir hydrate |
Grazoprevir hydrate (MK-5172 hydrate) is a selective of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. |
|
| DC42276 |
Sofosbuvir impurity F |
Sofosbuvir impurity F, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity. |
|
| DC42277 |
Sofosbuvir impurity K |
Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity. |
|
| DC42278 |
Sofosbuvir impurity H |
Sofosbuvir impurity H, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity. |
|
| DC42279 |
Sofosbuvir impurity J |
Sofosbuvir impurity J, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity. |
|
| DC42280 |
Sofosbuvir impurity L |
Sofosbuvir impurity L, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity. |
|
| DC42458 |
BMS-986144
Featured
|
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection. |
.png)
|
| DC44117 |
HCV-IN-31 |
HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC50/EC95 of 15.7 μM for HCV replicon. |
|
| DC44917 |
2'-O-Methylcytidine |
2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate. |
|
| DC45894 |
Oenothein B |
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase. |
|
| DC45938 |
Dehydrojuncusol |
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35 µM). |
|
| DC46154 |
AZD-7295 |
AZD-7295 is a HCV NS5A protein inhibitor, with an EC50 of 7 nM for GT-1b replicon. |
|
| DC46371 |
IDX184 |
IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM). |
|
| DC46624 |
HCV-IN-29 |
HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e. |
|
| DC46625 |
HCV-IN-30
Featured
|
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively. |
|
| DC46813 |
ABT-072 potassium trihydrate |
ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC50=1 nM; HCV GT1b EC50=0.3 nM). |
|
| DC47175 |
Valopicitabine dihydrochloride |
Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable prodrug of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination. |
|
| DC48097 |
ASP5286 |
ASP5286 is a novel non-immunosuppressive cyclophilin inhibitor for the treatment of HCV. |
|
| DC48407 |
NS5A-IN-1 |
NS5A-IN-1 is a prodrug of the HCV NS5A inhibitor Pibrentasvir (ABT-530). |
|
| DC49233 |
Coblopasvir dihydrochloride |
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection. |
|
| DC49480 |
GSK8175
Featured
|
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons. |
|
| DC49481 |
UK-1 |
UK-1 is a cytotoxic metabolite from Streptomyces sp. 517-02 and exerts a wide spectrum of potent anticancer activities. UK-1 also inhibits HCV replication. |
|
| DC70077 |
GSK-2485852 |
GSK-2485852 (GSK2485852, GSK5852) is a highly potent, selective HCV NS5B polymerase inhibitor with IC50 of 3.0 and 1.6 nM for HCV genotypes 1a and 1b in replicon assay, respectively. |
|
| DC70080 |
GSK-2878175 |
GSK-2878175 (GSK8175, GSK-175, GSK-175A) is a potent, pan-genotypic, second generation HCV NS5B palm polymerase inhibitor with EC50 of 0.4-9.7 nM. |
|
| DC70124 |
GSK-625433 |
A highly potent, selective HCV NS5B polymerase inhibitor for treatment of HCV infection. |
|
| DC70192 |
Amphihevir |
Amphihevir is a potent, selective HCV NS4B inhibitor with EC50 of 0.34 and 1.97 nM against the GT1a (H77) and GT1b replicon in luciferase assays.Amphihevir shows weaker acitivity against GT2a (JFH-1) (EC50=186 nM).Amphihevir shows EC50 3.13 nM and 18.16 nM with 100% human serum against GT1a and GT1b replicons using HCV-1b replicon cells test.Amphihevir reduced replicon RNA by nearly 6,300-fold (3.8 log10) at a concentration 25-fold greater than the EC90 (300 nM).Amphihevir was found to be inactive against other viruses, human kinases, and GPCRs, which implies its good selectivity.Amphihevir has good oral bioavailability and appropriate T1/2 in rats and dogs, showed good safety profiles in rats and dogs.Amphihevir is the first reported NS4B inhibitor that has advanced to clinical trials. |
|
| DC70356 |
Dichlorcyclizine |
Dichlorcyclizine (DCCZ) is a potent, small molecule HCV fusion inhibitor, also inhibits SARS-CoV and SARS-CoV-2 S-mediated infection in MA104 cells with EC50 of 9.92 and 4.53 uM, respectively. |
|
| DC70414 |
Fluoxazolevir |
Fluoxazolevir (NCGC00351982) is a potent, small molecule entry inhibitor of HCV with EC50 of 18.8 nM.Fluoxazolevir inhibits fusion of HCV with hepatic cells by binding HCV envelope protein 1 (E1) to prevent fusion.Fluoxazolevir was generally effective against all chimeric HCV-RLuc genotypes including 1a, 1b, 2b, 3a, 4a, 5a, 6a and 7a, was most effective against HCV 2a and 2b, followed by 3a and 6a, all within sub-μM EC50 values, with little to no cytotoxicity (CC50>20 uM).Fluoxazolevir was highly synergistic with other anti-HCV drugs (interferon-α, ribavirin, daclatasvir, sofosbuvir and simeprevir (NS3/4A protease inhibitor)).Fluoxazolevir suppresses HCV infection in humanized chimeric mice, and is active against multidrug-resistant HCV.Fluoxazolevir also broadly blocked human coronavirus entry into various cell types, inhibit SARS-CoV S- and SARS-CoV-2 S-mediated infection MA104 cells with EC50 of 6.49 and 3.86 uM, respectively. |
|
